Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line
Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.
Is this the biomarker breakthrough Longeveron Inc. needs to reach Phase 3?
Can biomarker-linked response boost laromestrocel’s Phase 3 prospects? Explore regulatory, financial, and industry implications.
Phase 3 analysis positions pritelivir as novel oral option for severe HSV in HIV
Phase 3 data position pritelivir as a novel oral option for severe HSV in HIV. Discover what this means for AiCuris and the antiviral market.
FDA approval of DESMODA positions Eton Pharmaceuticals for rare endocrine growth
Eton Pharmaceuticals wins FDA approval for DESMODA. Explore whether liquid desmopressin can reshape central diabetes insipidus care.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.
Stability data and strategy: PharmAla Biotech Holdings Inc. builds commercial groundwork for LaNeo MDMA
PharmAla Biotech Holdings Inc. launches a three-year stability program for LaNeo MDMA. Discover how this could reshape psychedelic drug commercialization.